2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 299-301

  Zhu, Xuejun ^a,b   Zhao, Guoming ^b   Zhou, Xiaoping ^a   Xu, Xiaoqian ^b,c   Xia, Guangqiang ^b   Zheng, Zhibing ^b   Wang, Lili ^b   Yang, Xiaohong ^a   Li, Song ^b  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

2,4 Diaryl 4,6,7,8 tetrahydroquinazolin 5(1H) one; Hepatitis B virus (HBV); Inhibitor; Nucleocapsid assembly

Indexed keywords

4,6,7,8 TETRAHYDROQUINAZOLIN 5(1H) ONE DERIVATIVE; ANTIVIRUS AGENT; BAY 41 4109; LAMIVUDINE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG DISCRIMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IC 50; NONHUMAN; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CAPSID; QUINAZOLINONES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HEPATITIS B VIRUS; MIRIDAE;

EID: 72049111233     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.119     Document Type: Article

References (30)

1. Ferir G., Kaptein S., and Neyts J. Rev. Med. Virol. 18 (2008) 19
2. Ghany M., and Liang T.J. Gastroenterology 132 (2007) 1574
3. Shaw T., and Bartholomeusz A. J. Hepatol. 44 (2006) 593
4. Clercq D.E. Exp. Opin. Emerg. Drugs 13 (2008) 393
5. Deres K., and Schroder C.H. Science 299 (2003) 893
6. Hacker H.J., and Deres K. Biochem. Pharmacol. 66 (2003) 2273
7. Stray S.J., and Zlotnick A. J. Mol. Rec. 19 (2006) 542
8. Block T.M., Lu X., Mehta A.S., and Ferir G. Nat. Med. 4 (1998) 610
9. Block T.M., and Jordan R. Antiviral. Chem. Chemother. 12 (2001) 317
10. Wen Y.-M., Lin X., and Ma Z.-M. Curr. Drug Targets 3 (2003) 241
11. Le Pogam S., Yuan T.-T., and Sahu G.K. J. Virol. 74 (2000) 9099
12. Chain B., Myers R., and Neyts J. BMC Microb. 5 (2005) 33
13. Choi I.-G., and Yu Y.G. Infect. Disorders-Drug Targets 7 (2007) 251
14. Zlotnick A., Ceres P., and Singh S. J. Virol. 76 (2002) 4848
15. King R.W., Ladner S.K., and Miller T.J. Antimicrob. Agents Chemother. 42 (1998) 3179
16. Stoltefuss, J.; Goldmann, S. WO Patent 9,954,326, 1999.
17. Goldmann, S.; Kramer, T. WO Patent 0,058,302, 2000.
18. Goldmann, S.; Stoltefuss, J. DE Patent 10,012,824A1, 2001.
19. Goldmann, S.; Stoltefuss, J.; U. Niewohner. DE Patent 10,013,126A1, 2001.
20. Goldmann, S.; Stoltefuss, J. U.S. Patent 6,503,913B1, 2003.
21. Weber O., Schlemmer K.H., and Hartmann E. Antiviral. Res. 54 (2002) 69
22. Bourne C., Finn M.G., and Zlotnick A. J. Virol. 80 (2006) 11055
23. Bourne C., Lee S., and Venkataiah B. J. Virol. 82 (2008) 10262
24. Slee H.D., Chen Y., and Zhang X. J. Med. Chem. 51 (2008) 1719
25. Kappe C.O. Tetrahedron 49 (1993) 6937
26. Judkins B.D., Allen D.G., and Cook T.A. Synth. Commun. 26 (1996) 4351
27. +).
28. Korba B.E., and Gerin J.L. Antiviral. Res. 19 (1992) 55
29. Sells M.A., Chen M.L., and Acs G. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 1005
30. Sells M.A., Zelent A.Z., and Shvartsman M. J. Virol. 62 (1988) 2836